Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001193125-26-084282
- form_type
- 8-K
- ticker
- URGN
- cik
- 0001668243
- company_name
- UroGen Pharma Ltd.
- filed_at
- 2026-03-02T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:35.816816+00:00
- generated_at
- 2026-05-15T22:40:54.988769+00:00
- sec_items
- ["1.01", "2.03"]
- event_type
- debt
- sentiment
- neutral
- materiality_score
- 0.75
- calibrated_materiality_score
- 0.75
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001193125-26-084282
- json_url
- https://secwatch.observer/filing/0001193125-26-084282.json
- markdown_url
- https://secwatch.observer/filing/0001193125-26-084282.md
- text_url
- https://secwatch.observer/filing/0001193125-26-084282.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1668243/000119312526084282/0001193125-26-084282-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1668243/000119312526084282/d59490d8k.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Source-grounded claims
75fd5a3c847541c2d4b8475408f85cdb1edb1bd7
UroGen Pharma Ltd. incurred term loan of up to $250,000,000, to be advanced in two tranches; Tranche A Loan of $200,000,000 funded; Tranche B Loan of $50,000,000 with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and BioPharma Credit PLC at 8.25% per annum fixed maturing 5th year anniversary of the Tranche A Closing Date.
On February 26, 2026, UroGen Pharma Ltd. (the “Company”), and UroGen Pharma, Inc., as the borrower (the “Borrower” and, together with the Company, collectively, the “Credit Parties”), entered into a loan agreement (the “Loan Agreement”) with BPCR Limited Partnership (as a “Lender”), BioPharma Credit Investments V (Master) LP (as a “Lender”), and BioPharma Credit PLC, as collateral agent for the Lenders (in such capacity, the “Collateral Agent”), pursuant to which the Lenders agreed to make term loans to the Borrower in an aggregate principal amount of up to $250,000,000, to be advanced in two tranches (the “Term Loans”).
SEC 8-K Item 2.03/2.04
confidence 0.99
SEC evidence
cc82681161e45eec4e881f7eb9c096f36dd80375
UroGen Pharma Ltd. entered into Loan Agreement with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and BioPharma Credit PLC valued at up to $250,000,000 (effective 2026-02-26).
On February 26, 2026, UroGen Pharma Ltd. (the “Company”), and UroGen Pharma, Inc., as the borrower (the “Borrower” and, together with the Company, collectively, the “Credit Parties”), entered into a loan agreement (the “Loan Agreement”) with BPCR Limited Partnership (as a “Lender”), BioPharma Credit Investments V (Master) LP (as a “Lender”), and BioPharma Credit PLC, as collateral agent for the Lenders (in such capacity, the “Collateral Agent”), pursuant to which the Lenders agreed to make term loans to the Borrower in an aggregate principal amount of up to $250,000,000, to be advanced in two tranches (the “Term Loans”).
SEC 8-K Item 1.01/1.02
confidence 0.9
SEC evidence
Comparable filings
BTU
Peabody prices $250M convertible notes due 2031, repurchases $241.2M of 2028 notes
PEABODY ENERGY CORP
June 2, 2026, 10:17 AM ET
debt
Items 1.01, 2.03, 3.02, 9.01
same fact type: debt_financing, material_agreement
same SEC item: 1.01, 2.03
same event type: debt
similar materiality
This filing
On February 26, 2026, UroGen Pharma Ltd. (the “Company”), and UroGen Pharma, Inc., as the borrower (the “Borrower” and, together with the Company, collectively, the “Credit Parties”), entered into a loan agreement (the “Loan Agreement”) with BPCR Limited Partnership (as a “Lender”), BioPharma Credit Investments V (Master) LP (as a “Lender”), and BioPharma Credit PLC, as collateral agent for the Lenders (in such capacity, the “Collateral Agent”), pursuant to which the Lenders agreed to make term loans to the Borrower in an aggregate principal amount of up to $250,000,000, to be advanced in two tranches (the “Term Loans”).
Comparable filing
additional $25 million in aggregate principal amount of the Notes (together with the “Initial Notes,” the “Notes”), bringing the total aggregate principal amount of the Notes to $250 million. On June 2, 2026, the Company completed the private offering of the Notes. The Notes are senior unsecured obligations of the Company. The net proceeds from this offering were
Filing page
SEC filing
CBLO
C2 Blockchain raises $130K and up to $1.2M via convertible notes with heavy dilution
C2 Blockchain, Inc.
June 2, 2026, 10:08 AM ET
debt
Items 1.01, 2.03, 3.02, 9.01
same fact type: debt_financing, material_agreement
same SEC item: 1.01, 2.03
same event type: debt
similar materiality
This filing
On February 26, 2026, UroGen Pharma Ltd. (the “Company”), and UroGen Pharma, Inc., as the borrower (the “Borrower” and, together with the Company, collectively, the “Credit Parties”), entered into a loan agreement (the “Loan Agreement”) with BPCR Limited Partnership (as a “Lender”), BioPharma Credit Investments V (Master) LP (as a “Lender”), and BioPharma Credit PLC, as collateral agent for the Lenders (in such capacity, the “Collateral Agent”), pursuant to which the Lenders agreed to make term loans to the Borrower in an aggregate principal amount of up to $250,000,000, to be advanced in two tranches (the “Term Loans”).
Comparable filing
On May 22, 2026, the Company entered into a Securities Purchase Agreement with Auctus Fund, LLC (“Auctus”), pursuant to which the Company issued and sold a Promissory Note in the principal amount of $130,000 (the “Auctus Note”).
Filing page
SEC filing
VVX
V2X refinances $868.5M term loans with new tranche maturing 2030; SOFR+2% margin
V2X, Inc.
June 1, 2026, 4:10 PM ET
debt
Items 1.01, 2.03, 9.01
same fact type: debt_financing, material_agreement
same SEC item: 1.01, 2.03
same event type: debt
similar materiality
This filing
On February 26, 2026, UroGen Pharma Ltd. (the “Company”), and UroGen Pharma, Inc., as the borrower (the “Borrower” and, together with the Company, collectively, the “Credit Parties”), entered into a loan agreement (the “Loan Agreement”) with BPCR Limited Partnership (as a “Lender”), BioPharma Credit Investments V (Master) LP (as a “Lender”), and BioPharma Credit PLC, as collateral agent for the Lenders (in such capacity, the “Collateral Agent”), pursuant to which the Lenders agreed to make term loans to the Borrower in an aggregate principal amount of up to $250,000,000, to be advanced in two tranches (the “Term Loans”).
Comparable filing
The Amendment provides for, among other things, a new tranche of term loans under the Credit Agreement in an aggregate original principal amount of $868,522,978.38 (the “New Term Loans”), which New Term Loans replace or refinance in full all of the existing term loans outstanding under the Credit Agreement (as in effect immediately prior to the Amendment), as further set forth in the Amendment. The New Term Loans mature on December 6, 2030.
Filing page
SEC filing
EMAT
EMAT secures $100M convertible debenture facility from Yorkville; first $20M tranche issued
Evolution Metals & Technologies Corp.
May 11, 2026, 7:59 PM ET
debt
Items 1.01, 2.03, 3.02, 7.01, 9.01
same fact type: debt_financing, material_agreement
same SEC item: 1.01, 2.03
same event type: debt
similar materiality
This filing
On February 26, 2026, UroGen Pharma Ltd. (the “Company”), and UroGen Pharma, Inc., as the borrower (the “Borrower” and, together with the Company, collectively, the “Credit Parties”), entered into a loan agreement (the “Loan Agreement”) with BPCR Limited Partnership (as a “Lender”), BioPharma Credit Investments V (Master) LP (as a “Lender”), and BioPharma Credit PLC, as collateral agent for the Lenders (in such capacity, the “Collateral Agent”), pursuant to which the Lenders agreed to make term loans to the Borrower in an aggregate principal amount of up to $250,000,000, to be advanced in two tranches (the “Term Loans”).
Comparable filing
The first Convertible Debenture (the “First Debenture”) in the principal amount of $20,000,000 was issued on May 7, 2026.
Filing page
SEC filing
AZZ
AZZ refinances revolver; maturity extended to 2029, margins cut 50 bps
AZZ INC
May 8, 2026, 7:59 PM ET
debt
Items 1.01, 2.03, 9.01
same fact type: debt_financing, material_agreement
same SEC item: 1.01, 2.03
same event type: debt
similar materiality
This filing
On February 26, 2026, UroGen Pharma Ltd. (the “Company”), and UroGen Pharma, Inc., as the borrower (the “Borrower” and, together with the Company, collectively, the “Credit Parties”), entered into a loan agreement (the “Loan Agreement”) with BPCR Limited Partnership (as a “Lender”), BioPharma Credit Investments V (Master) LP (as a “Lender”), and BioPharma Credit PLC, as collateral agent for the Lenders (in such capacity, the “Collateral Agent”), pursuant to which the Lenders agreed to make term loans to the Borrower in an aggregate principal amount of up to $250,000,000, to be advanced in two tranches (the “Term Loans”).
Comparable filing
The Seventh Amendment (i) terminated the Initial Revolving Credit Commitments and simultaneously replaced them in their entirety with Extended Revolving Credit Commitments having a Maturity Date of May 7, 2029, (ii) decreased the interest rate margin applicable to the Revolving Credit Loans from margins ranging from 175 basis points to 275 basis points (subject to leverage ratio step-downs) to margins ranging from 125 basis points to 225 basis points (subject to leverage ratio step-downs)
Filing page
SEC filing
ILPT
ILPT Mountain JV closes $1.62B loan at 5.71% fixed, repays $1.6B existing debt
Industrial Logistics Properties Trust
May 8, 2026, 7:59 PM ET
debt
Items 1.01, 1.02, 2.03, 9.01
same fact type: debt_financing, material_agreement
same SEC item: 1.01, 2.03
same event type: debt
similar materiality
This filing
On February 26, 2026, UroGen Pharma Ltd. (the “Company”), and UroGen Pharma, Inc., as the borrower (the “Borrower” and, together with the Company, collectively, the “Credit Parties”), entered into a loan agreement (the “Loan Agreement”) with BPCR Limited Partnership (as a “Lender”), BioPharma Credit Investments V (Master) LP (as a “Lender”), and BioPharma Credit PLC, as collateral agent for the Lenders (in such capacity, the “Collateral Agent”), pursuant to which the Lenders agreed to make term loans to the Borrower in an aggregate principal amount of up to $250,000,000, to be advanced in two tranches (the “Term Loans”).
Comparable filing
Stanley Bank, N.A., Bank of America, N.A., Bank of Montreal and UBS AG New York Branch, or collectively,
the lenders, pursuant to which Mountain JV obtained, in aggregate, a $1.62 billion loan secured
by 90 of its properties, or the Loan . Also on May 8, 2026, we entered into a guaranty in favor of the lenders, pursuant to which
we guaranteed certain limited
Filing page
SEC filing
TBH
Brag House issues $2.5M convertible notes at 25% OID; proceeds for House of Doge merger
Brag House Holdings, Inc.
May 8, 2026, 7:59 PM ET
debt
Items 1.01, 2.03, 3.02, 9.01
same fact type: debt_financing, material_agreement
same SEC item: 1.01, 2.03
same event type: debt
similar materiality
This filing
On February 26, 2026, UroGen Pharma Ltd. (the “Company”), and UroGen Pharma, Inc., as the borrower (the “Borrower” and, together with the Company, collectively, the “Credit Parties”), entered into a loan agreement (the “Loan Agreement”) with BPCR Limited Partnership (as a “Lender”), BioPharma Credit Investments V (Master) LP (as a “Lender”), and BioPharma Credit PLC, as collateral agent for the Lenders (in such capacity, the “Collateral Agent”), pursuant to which the Lenders agreed to make term loans to the Borrower in an aggregate principal amount of up to $250,000,000, to be advanced in two tranches (the “Term Loans”).
Comparable filing
The issuance of the Notes in the aggregate original principal amount of $2,500,000 constitutes the creation of a direct financial obligation of the Company. The Notes bear interest at 12.0% per annum, mature on February 4, 2027
Filing page
SEC filing
KNX
Knight-Swift closes $1.5B convertible note offering at 1.00% due 2031; proceeds used to repay term loans and revolver
Knight-Swift Transportation Holdings Inc.
May 8, 2026, 7:59 PM ET
debt
Items 1.01, 2.03, 3.02, 8.01, 9.01
same fact type: debt_financing, material_agreement
same SEC item: 1.01, 2.03
same event type: debt
similar materiality
This filing
On February 26, 2026, UroGen Pharma Ltd. (the “Company”), and UroGen Pharma, Inc., as the borrower (the “Borrower” and, together with the Company, collectively, the “Credit Parties”), entered into a loan agreement (the “Loan Agreement”) with BPCR Limited Partnership (as a “Lender”), BioPharma Credit Investments V (Master) LP (as a “Lender”), and BioPharma Credit PLC, as collateral agent for the Lenders (in such capacity, the “Collateral Agent”), pursuant to which the Lenders agreed to make term loans to the Borrower in an aggregate principal amount of up to $250,000,000, to be advanced in two tranches (the “Term Loans”).
Comparable filing
On May 8, 2026, Knight-Swift Transportation Holdings Inc. (the "Company") completed its previously announced private offering (the "Offering") of $1.5 billion aggregate principal amount of 1.00% Convertible Senior Notes due 2031
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.